Last reviewed · How we verify
Trichloroform (CHLOROFORM)
Chloroform, a general anesthetic agent, is currently marketed but lacks a specified primary indication or revenue data. Its key strength lies in its well-established mechanism of action through the central nervous system, which has been utilized for inducing anesthesia. However, the primary risk is the competitive landscape, with multiple off-patent alternatives such as halothane, enflurane, isoflurane, desflurane, and sevoflurane, all of which are widely available as generics.
At a glance
| Generic name | CHLOROFORM |
|---|---|
| Drug class | chloroform |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- miRNA in Pediatric Gastritis (NA)
- Hormone Secretion in Transgender Males (PHASE4)
- Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus (EARLY_PHASE1)
- Post Extraction Changes Following Ridge Preservation Using Allogenis Dentin Vs Autogenous Partially Demineralized Dentin (NA)
- Post Extraction Changes After Ridge Preservation Using Allogeneic Dentin Matrix Vs Demineralized Freeze Dried Allograft (NA)
- Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids (PHASE1)
- Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial (PHASE3)
- The Impact of Ashwagandha on Perceived Stress, Sleep and Food Cravings in College Students (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trichloroform CI brief — competitive landscape report
- Trichloroform updates RSS · CI watch RSS